A Dose Block-randomized, Double-blind, Placebo Controlled, Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of DWP10292 and Ursodeoxycholic Acid in Healthy Male Subjects

Trial Profile

A Dose Block-randomized, Double-blind, Placebo Controlled, Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of DWP10292 and Ursodeoxycholic Acid in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs DWP 10292 (Primary) ; Ursodeoxycholic acid
  • Indications Non-alcoholic fatty liver disease
  • Focus Pharmacokinetics
  • Sponsors Daewoong Pharmaceutical
  • Most Recent Events

    • 01 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 26 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
    • 09 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top